These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 34084223)
1. Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib-resistant non-small cell lung cancer cells. Yang Y; Wang Y; Che X; Hou K; Wu J; Zheng C; Cheng Y; Liu Y; Hu X; Zhang J Oncol Lett; 2021 Jul; 22(1):556. PubMed ID: 34084223 [TBL] [Abstract][Full Text] [Related]
2. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer. Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257 [TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib. Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023 [TBL] [Abstract][Full Text] [Related]
4. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines. Li K; Zhou F; Zhou Y; Zhang S; Li Q; Li Z; Liu L; Wu G; Meng R Int J Mol Med; 2019 Aug; 44(2):437-446. PubMed ID: 31173177 [TBL] [Abstract][Full Text] [Related]
5. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms]. Zhou Y; Zhang S; Li K; Li QW; Zhou FZ; Li ZY; Ma H; Dong XR; Liu L; Wu G; Meng R Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):100-4. PubMed ID: 26899328 [TBL] [Abstract][Full Text] [Related]
6. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936 [TBL] [Abstract][Full Text] [Related]
7. Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo. Liu T; Jin L; Lu W; Gan H; Lin Z; Chen M; Liu J; Zhang F; Wang S; Zhang H; Deng W; Chen H J Exp Clin Cancer Res; 2019 Apr; 38(1):148. PubMed ID: 30953548 [TBL] [Abstract][Full Text] [Related]
8. Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC. Yu Y; Abudula M; Li C; Chen Z; Zhang Y; Chen Y Respir Res; 2019 Oct; 20(1):217. PubMed ID: 31606039 [TBL] [Abstract][Full Text] [Related]
9. Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway. Deng QF; Su BO; Zhao YM; Tang L; Zhang J; Zhou CC Oncol Lett; 2016 Jan; 11(1):535-542. PubMed ID: 26870244 [TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407 [TBL] [Abstract][Full Text] [Related]
11. Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib. Zhai Y; Zhang Y; Nan K; Liang X Oncol Lett; 2017 May; 13(5):3233-3238. PubMed ID: 28521430 [TBL] [Abstract][Full Text] [Related]
13. A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib. Huang J; Yu Q; Zhou Y; Chu Y; Jiang F; Zhu X; Zhang J; Wang Q Transl Cancer Res; 2020 Feb; 9(2):1044-1052. PubMed ID: 35117449 [TBL] [Abstract][Full Text] [Related]
14. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer]. Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053 [TBL] [Abstract][Full Text] [Related]
15. Fut7 Promotes Adhesion and Invasion of Acute Lymphoblastic Leukemia Cells through the Integrin/Fak/Akt Pathway. He F; Yi L; Lai C Evid Based Complement Alternat Med; 2022; 2022():1864116. PubMed ID: 35795270 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-7 inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells by targeting FAK through ERK/MAPK signaling pathway. Cao Q; Mao ZD; Shi YJ; Chen Y; Sun Y; Zhang Q; Song L; Peng LP Oncotarget; 2016 Nov; 7(47):77468-77481. PubMed ID: 27764812 [TBL] [Abstract][Full Text] [Related]
17. Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib. Lyu X; Zeng L; Shi J; Ming Z; Li W; Liu B; Chen Y; Yuan B; Sun R; Yuan J; Zhao N; Yang X; Chen G; Yang S J Exp Clin Cancer Res; 2022 Jun; 41(1):200. PubMed ID: 35690866 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264 [TBL] [Abstract][Full Text] [Related]
19. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities. Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282 [TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. Tang N; Zhang Q; Fang S; Han X; Wang Z Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]